Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.11
CRL's Cash-to-Debt is ranked lower than
89% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. CRL: 0.11 )
Ranked among companies with meaningful Cash-to-Debt only.
CRL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.28 Max: 15.68
Current: 0.11
0.04
15.68
Equity-to-Asset 0.31
CRL's Equity-to-Asset is ranked lower than
82% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. CRL: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
CRL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.28  Med: 0.43 Max: 0.72
Current: 0.31
-0.28
0.72
Debt-to-Equity 1.55
CRL's Debt-to-Equity is ranked lower than
84% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. CRL: 1.55 )
Ranked among companies with meaningful Debt-to-Equity only.
CRL' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.68  Med: 0.65 Max: 1.8
Current: 1.55
-3.68
1.8
Debt-to-EBITDA 3.94
CRL's Debt-to-EBITDA is ranked lower than
61% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. CRL: 3.94 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CRL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.42  Med: 2.65 Max: 3.94
Current: 3.94
-3.42
3.94
Interest Coverage 6.22
CRL's Interest Coverage is ranked lower than
69% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. CRL: 6.22 )
Ranked among companies with meaningful Interest Coverage only.
CRL' s Interest Coverage Range Over the Past 10 Years
Min: 3.62  Med: 8.2 Max: 17.86
Current: 6.22
3.62
17.86
Piotroski F-Score: 4
Altman Z-Score: 2.35
Beneish M-Score: -2.55
WACC vs ROIC
6.25%
6.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 13.91
CRL's Operating Margin % is ranked higher than
83% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. CRL: 13.91 )
Ranked among companies with meaningful Operating Margin % only.
CRL' s Operating Margin % Range Over the Past 10 Years
Min: 11.28  Med: 14.58 Max: 18.63
Current: 13.91
11.28
18.63
Net Margin % 6.38
CRL's Net Margin % is ranked higher than
71% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. CRL: 6.38 )
Ranked among companies with meaningful Net Margin % only.
CRL' s Net Margin % Range Over the Past 10 Years
Min: -38.84  Med: 9.01 Max: 10.95
Current: 6.38
-38.84
10.95
ROE % 12.05
CRL's ROE % is ranked higher than
80% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. CRL: 12.05 )
Ranked among companies with meaningful ROE % only.
CRL' s ROE % Range Over the Past 10 Years
Min: -34.11  Med: 16.92 Max: 21.25
Current: 12.05
-34.11
21.25
ROA % 4.18
CRL's ROA % is ranked higher than
69% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. CRL: 4.18 )
Ranked among companies with meaningful ROA % only.
CRL' s ROA % Range Over the Past 10 Years
Min: -21.02  Med: 6.29 Max: 7.58
Current: 4.18
-21.02
7.58
ROC (Joel Greenblatt) % 34.90
CRL's ROC (Joel Greenblatt) % is ranked higher than
77% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. CRL: 34.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -50.32  Med: 19.85 Max: 38.57
Current: 34.9
-50.32
38.57
3-Year Revenue Growth Rate 11.90
CRL's 3-Year Revenue Growth Rate is ranked higher than
65% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. CRL: 11.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 7 Max: 13.4
Current: 11.9
-17.6
13.4
3-Year EBITDA Growth Rate 16.20
CRL's 3-Year EBITDA Growth Rate is ranked higher than
63% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. CRL: 16.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.8 Max: 16.2
Current: 16.2
0
16.2
3-Year EPS without NRI Growth Rate -2.00
CRL's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. CRL: -2.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3 Max: 27.3
Current: -2
0
27.3
GuruFocus has detected 4 Warning Signs with Charles River Laboratories International Inc CRL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRL's 30-Y Financials

Financials (Next Earnings Date: 2018-11-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

CRL Guru Trades in Q3 2017

Joel Greenblatt 45,906 sh (+1896.78%)
Pioneer Investments 131,661 sh (+32.84%)
Jim Simons 1,339,709 sh (+9.82%)
Jeremy Grantham 3,200 sh (unchged)
Paul Tudor Jones Sold Out
Ken Fisher 452,156 sh (-1.18%)
PRIMECAP Management 426,200 sh (-5.92%)
John Rogers 1,680,066 sh (-13.86%)
Robert Olstein 60,112 sh (-22.07%)
Ray Dalio 2,574 sh (-61.63%)
» More
Q4 2017

CRL Guru Trades in Q4 2017

Mario Gabelli 5,000 sh (New)
Pioneer Investments 190,070 sh (+44.36%)
Jeremy Grantham 3,500 sh (+9.38%)
Jim Simons 1,398,700 sh (+4.40%)
Joel Greenblatt Sold Out
Ray Dalio Sold Out
PRIMECAP Management 425,900 sh (-0.07%)
Ken Fisher 436,028 sh (-3.57%)
John Rogers 1,353,195 sh (-19.46%)
Robert Olstein 48,235 sh (-19.76%)
» More
Q1 2018

CRL Guru Trades in Q1 2018

Joel Greenblatt 2,750 sh (New)
Ray Dalio 12,245 sh (New)
Mario Gabelli 7,000 sh (+40.00%)
Jim Simons 1,460,300 sh (+4.40%)
John Rogers 1,361,277 sh (+0.60%)
Jeremy Grantham Sold Out
Robert Olstein Sold Out
PRIMECAP Management 424,300 sh (-0.38%)
Ken Fisher 378,620 sh (-13.17%)
Pioneer Investments 17,159 sh (-90.97%)
» More
Q2 2018

CRL Guru Trades in Q2 2018

Richard Pzena 2,225 sh (New)
Mario Gabelli 9,000 sh (+28.57%)
Jim Simons 1,515,300 sh (+3.77%)
Pioneer Investments Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 424,100 sh (-0.05%)
John Rogers 1,317,586 sh (-3.21%)
Ken Fisher 364,739 sh (-3.67%)
Ray Dalio 10,505 sh (-14.21%)
» More
» Details

Insider Trades

Latest Guru Trades with CRL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Rogers 2018-06-30 Reduce -3.21%0.05%$102.37 - $117.25 $ 121.1312%1,317,586
Ken Fisher 2018-06-30 Reduce -3.67%$102.37 - $117.25 $ 121.1312%364,739
Mario Gabelli 2018-06-30 Add 28.57%$102.37 - $117.25 $ 121.1312%9,000
Richard Pzena 2018-06-30 New Buy$102.37 - $117.25 $ 121.1312%2,225
Joel Greenblatt 2018-06-30 Sold Out $102.37 - $117.25 $ 121.1312%0
John Rogers 2018-03-31 Add 0.60%0.01%$98.19 - $115.2 $ 121.1312%1,361,277
Ken Fisher 2018-03-31 Reduce -13.17%0.01%$98.19 - $115.2 $ 121.1312%378,620
Mario Gabelli 2018-03-31 Add 40.00%$98.19 - $115.2 $ 121.1312%7,000
Joel Greenblatt 2018-03-31 New Buy$98.19 - $115.2 $ 121.1312%2,750
Robert Olstein 2018-03-31 Sold Out 0.67%$98.19 - $115.2 $ 121.1312%0
John Rogers 2017-12-31 Reduce -19.46%0.41%$100.43 - $118.09 $ 121.1311%1,353,195
Ken Fisher 2017-12-31 Reduce -3.57%$100.43 - $118.09 $ 121.1311%436,028
Robert Olstein 2017-12-31 Reduce -19.76%0.17%$100.43 - $118.09 $ 121.1311%48,235
Mario Gabelli 2017-12-31 New Buy$100.43 - $118.09 $ 121.1311%5,000
Joel Greenblatt 2017-12-31 Sold Out 0.07%$100.43 - $118.09 $ 121.1311%0
John Rogers 2017-09-30 Reduce -13.86%0.32%$96.72 - $109.26 $ 121.1318%1,680,066
Ken Fisher 2017-09-30 Reduce -1.18%$96.72 - $109.26 $ 121.1318%452,156
Robert Olstein 2017-09-30 Reduce -22.07%0.22%$96.72 - $109.26 $ 121.1318%60,112
Joel Greenblatt 2017-09-30 Add 1896.78%0.07%$96.72 - $109.26 $ 121.1318%45,906
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541714    SIC: 8732
Compare:MIL:DIA, NAS:BRKR, NAS:PRAH, SHSE:603658, NAS:SYNH, XTER:AFX, NAS:EXAS, NAS:ICLR, NAS:DXCM, NAS:NEOG, NAS:FMI, NYSE:QGEN, BSP:DASA3, BSP:FLRY3, SZSE:300463, NYSE:BIO, TSE:4544, SHSE:603882, SZSE:300482, NAS:QDEL » details
Traded in other countries:RV6.Germany,
Headquarter Location:USA
Charles River Laboratories International Inc is a pharmaceutical company providing drug discovery and development services. The company provides animal models for laboratory testing, and offers manufacturing testing services to various industries.

Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. The remainder of Charles River's revenue comes from its preclinical services segment, which offers discovery, toxicology, pathology, and manufacturing testing services to pharmaceutical, biotechnology, and device companies.

Guru Investment Theses on Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl - Jan 20, 2017

Other holdings underperformed. Scientific research firm Charles River Laboratories Intl, Inc. (NYSE:CRL) slid –8.58% due to contracting customer spending and a general downturn in health care stocks. Like other similar firms, Charles River expanded over the last 15 years to be able to handle peak medical research, but as drug companies scaled back, there was clearly overcapacity. The company’s drug discovery business is still a bit slack. That said, many health care stocks slid this quarter during a huge rotation to financials. We think the current issues are largely cyclical but the secular push toward solving medical problems through pharmaceuticals remains intact—a long-term tailwind for Charles River.



From John Rogers (Trades, Portfolio)' Ariel Fund fourth quarter 2016 commentary.



Check out John Rogers latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 45.89
CRL's PE Ratio is ranked lower than
66% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. CRL: 45.89 )
Ranked among companies with meaningful PE Ratio only.
CRL' s PE Ratio Range Over the Past 10 Years
Min: 8.58  Med: 24.87 Max: 95.66
Current: 45.89
8.58
95.66
Forward PE Ratio 20.83
CRL's Forward PE Ratio is ranked higher than
75% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 20.83 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 46.64
CRL's PE Ratio without NRI is ranked lower than
65% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. CRL: 46.64 )
Ranked among companies with meaningful PE Ratio without NRI only.
CRL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.51  Med: 24.77 Max: 77.86
Current: 46.64
8.51
77.86
Price-to-Owner-Earnings 21.37
CRL's Price-to-Owner-Earnings is ranked higher than
70% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. CRL: 21.37 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CRL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.56  Med: 21.58 Max: 323.25
Current: 21.37
10.56
323.25
PB Ratio 4.92
CRL's PB Ratio is ranked lower than
57% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. CRL: 4.92 )
Ranked among companies with meaningful PB Ratio only.
CRL' s PB Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.42 Max: 6.01
Current: 4.92
0.75
6.01
PS Ratio 2.91
CRL's PS Ratio is ranked higher than
60% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. CRL: 2.91 )
Ranked among companies with meaningful PS Ratio only.
CRL' s PS Ratio Range Over the Past 10 Years
Min: 1.12  Med: 2.22 Max: 3.83
Current: 2.91
1.12
3.83
Price-to-Free-Cash-Flow 22.23
CRL's Price-to-Free-Cash-Flow is ranked higher than
61% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. CRL: 22.23 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CRL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.56  Med: 16.84 Max: 1041.48
Current: 22.23
8.56
1041.48
Price-to-Operating-Cash-Flow 16.11
CRL's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. CRL: 16.11 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CRL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.82  Med: 12.16 Max: 19.18
Current: 16.11
4.82
19.18
EV-to-EBIT 23.29
CRL's EV-to-EBIT is ranked higher than
67% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. CRL: 23.29 )
Ranked among companies with meaningful EV-to-EBIT only.
CRL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 18.5 Max: 27.8
Current: 23.29
-10.7
27.8
EV-to-EBITDA 16.06
CRL's EV-to-EBITDA is ranked higher than
71% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. CRL: 16.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.5  Med: 12.5 Max: 17
Current: 16.06
-16.5
17
EV-to-Revenue 3.67
CRL's EV-to-Revenue is ranked higher than
57% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. CRL: 3.67 )
Ranked among companies with meaningful EV-to-Revenue only.
CRL' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.4  Med: 2.7 Max: 4.1
Current: 3.67
1.4
4.1
PEG Ratio 3.46
CRL's PEG Ratio is ranked lower than
52% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. CRL: 3.46 )
Ranked among companies with meaningful PEG Ratio only.
CRL' s PEG Ratio Range Over the Past 10 Years
Min: 1.55  Med: 2.91 Max: 81.03
Current: 3.46
1.55
81.03
Shiller PE Ratio 200.69
CRL's Shiller PE Ratio is ranked lower than
97% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. CRL: 200.69 )
Ranked among companies with meaningful Shiller PE Ratio only.
CRL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 90.11  Med: 166.28 Max: 1940.5
Current: 200.69
90.11
1940.5
Current Ratio 1.72
CRL's Current Ratio is ranked lower than
66% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. CRL: 1.72 )
Ranked among companies with meaningful Current Ratio only.
CRL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.98 Max: 3.49
Current: 1.72
1.21
3.49
Quick Ratio 1.48
CRL's Quick Ratio is ranked lower than
65% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. CRL: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
CRL' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.66 Max: 3.02
Current: 1.48
0.95
3.02
Days Inventory 32.53
CRL's Days Inventory is ranked higher than
73% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. CRL: 32.53 )
Ranked among companies with meaningful Days Inventory only.
CRL' s Days Inventory Range Over the Past 10 Years
Min: 32.53  Med: 41.32 Max: 49.49
Current: 32.53
32.53
49.49
Days Sales Outstanding 66.82
CRL's Days Sales Outstanding is ranked higher than
52% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. CRL: 66.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.63  Med: 58.65 Max: 66.82
Current: 66.82
49.63
66.82
Days Payable 19.25
CRL's Days Payable is ranked lower than
88% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. CRL: 19.25 )
Ranked among companies with meaningful Days Payable only.
CRL' s Days Payable Range Over the Past 10 Years
Min: 14.93  Med: 15.77 Max: 24.59
Current: 19.25
14.93
24.59

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.40
CRL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
76% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. CRL: 1.40 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CRL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.33 Max: 1.94
Current: 1.4
0.94
1.94
Price-to-Median-PS-Value 1.32
CRL's Price-to-Median-PS-Value is ranked lower than
65% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. CRL: 1.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.22 Max: 1.85
Current: 1.32
0.55
1.85
Price-to-Peter-Lynch-Fair-Value 3.09
CRL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
77% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. CRL: 3.09 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CRL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.62  Med: 2.59 Max: 4.02
Current: 3.09
1.62
4.02
Earnings Yield (Greenblatt) % 4.29
CRL's Earnings Yield (Greenblatt) % is ranked higher than
85% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. CRL: 4.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -24.3  Med: 5.1 Max: 14.4
Current: 4.29
-24.3
14.4
Forward Rate of Return (Yacktman) % 19.07
CRL's Forward Rate of Return (Yacktman) % is ranked higher than
80% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. CRL: 19.07 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CRL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.2  Med: 5.3 Max: 19.5
Current: 19.07
1.2
19.5

More Statistics

Revenue (TTM) (Mil) $2,021.98
EPS (TTM) $ 2.64
Beta0.72
Volatility21.36%
52-Week Range $96.70 - 130.66
Shares Outstanding (Mil)48.03

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 2,217 2,415 2,563
EBIT (Mil $) 367 424 478
EBITDA (Mil $) 499 565 611
EPS ($) 4.93 5.77 6.54
EPS without NRI ($) 4.93 5.77 6.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.59%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}